

BioBusiness Asia 2009

| | | | |
|--------------------|--|--------------------|------|
| Company Name | CEVEC Pharmaceuticals GmbH | | |
| Presenter | Rainer Lichtenberger, PH.D. | Title | CEO |
| Address | Gottfried-Hagen-Strasse 62, 51105 Köln, Germany | | |
| Website | www.cevec-pharmaceuticals.com | | |
| No. of employee | 15 | Year of foundation | 2001 |
| Company Categories | <input type="checkbox"/> Novel Therapeutics x Genomics <input type="checkbox"/> Pharmaceuticals <input checked="" type="checkbox"/> R&D Service <input type="checkbox"/> Medical Devices x Other: human production cell lines_ | | |
| Paid-in Capital | 8 Mio. € | | |
| Company Stage | <input type="checkbox"/> Seed <input type="checkbox"/> Start up x Expansion <input type="checkbox"/> Mezzanine | | |
| Company Overview | <p>The increasing demand for quality, identity, and high yields in biopharmaceutical protein manufacturing has driven the development of new expression systems over the last decade. Human cell-based systems have a huge potential as future technology for the production of human therapeutic proteins. With its CAP[®] cell line, CEVEC has developed a new expression system which is based on using human amniocytes and which offers significant advantages over currently existing production technologies. Amniocytes are cells derived from the amniotic fluid which are collected by amniocentesis, a clinical routine procedure. Using amniocytes from amniocentesis samples not needed for cytogenetic analysis by CEVEC is done strictly adhering to all legal and ethical requirements, including ethics committee approval and donor informed consent. Their unique features include comprehensive documentation, safety, ethically accepted cell source, non-tumor origin, and growth as suspension culture in serum- and protein-free media optimized for industrial use, even in large-scale.</p> | | |

| | |
|---|---|
| Company History | <p>CEVEC Pharmaceuticals GmbH, has been founded in 2001 as a university spin-off of the University of Cologne, Germany. CEVEC is specialized in developing and out-licensing of complex therapeutic proteins based on its own proprietary human cellular expression platform. CEVEC offers the new CAP-T™ transient expression system for licensing by pharma and biotech industry since March 2009. This new high-performance system for transient expression of recombinant proteins is the logical result of today's demands for a flexible and efficient, fast, integrated and comprehensively documented platform for production of complex therapeutic proteins and antibodies. From cDNA cloning to gram amounts of high-quality protein in two weeks – this is what CEVEC now can promise approaching its customers. Fast development timelines, high yields and authentic human protein glycosylation or sialylation are the major upsides of this new system, especially for complex proteins such as highly glycosylated or multi-chain polypeptides. For screening, target validation, assay development and other demanding cell-based R&D procedures, the new CAP-T™ system is perfectly positioned to serve as the ideal tool for recombinant protein expression in the biopharmaceutical environment. As Dr. Rainer Lichtenberger, CEVEC's CEO, comments: "From transient protein expression using CAP-T™ for research purposes all the way to development of permanent producer cell lines for market supply based on CAP® cell technology, CEVEC is able to cover the entire production spectrum. This means our customers can stay with the same efficient and high-performing cell line system from the early research idea to the GMP-compliant protein production for clinical trial material and market supply – saving time, risk and costs of changing cell systems during the course of biopharmaceutical product development in the future. CEVEC is well-known in the market for commercializing its CAP® cell line, a platform technology for the production of biopharmaceuticals on the basis of human cell lines, and the development of selected protein therapeutics in CAP® cells. CAP-T™ cells are based on CAP® cells and match all their positive features with regard to comprehensive documentation, safety, ethically accepted cell source, non-tumor origin, and growth as suspension culture in serum- and protein-free media optimized for industrial use, even in large-scale. The produce proteins in very high yields up to several grams per litre.</p> |
| Main Products/ Service & Niche of Products/ Service | <p>CAP Cevec Amniocyte cell expression system CAP-T Cevec transient aminiocyte cell expression system Research and Development Licenses, cell line development services</p> |
| Market Potentials | <p>Market for all biopharmaceutical protein expression systems, especially those with high demands for quality and post-translational modifications</p> |
| Company Core Competence or Competitive Advantage | <p>Only stable and fully documented human cell line for protein cell expression, very robust, serum-free growth, high yield in suspension culture, very rapid and high yield transient protein expression system. Only world-wide available system for transient and permanent protein expression from one cell origin.</p> |
| Partnering Objectives | <p>Identify and partner with interested Contract Manufacturing Organisations and Pharma/Biotech companies. Interested to meet lab trading partners which cover Asian academia and research institutions with own sales forces.</p> |